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Background
The efficacy of MP29-02* (a novel intranasal formulation
of azelastine hydrochloride [AZE] and fluticasone propio-
nate [FP] in an advanced delivery system) in providing
overall nasal and ocular symptom relief vs AZE, FP or
placebo (PLA) has been assessed.
Methods
Six hundred and ten moderate-to-severe SAR patients
(≥12 yrs) were randomized into a double-blind, PLA-
controlled, 14-day, parallel-group, trial (NCT00660517)
to MP29-02*, AZE, FP or PLA nasal sprays (1 spray/
nostril bd; daily dose: AZE=548μg; FP=200μg) [1].
Change from baseline (CFB) in reflective total of 7 symp-
tom scores (rT7SS; AM + PM, max=42) was assessed
post-hoc. CFB in rT7SS and each nasal (congestion, itch-
ing, rhinorrhea, sneezing) and ocular symptom (itching,
redness, watering; max=6 each) was assessed over time.
Results
Overall, MP29-02* patients showed greater reduction in
rT7SS vs FP, AZE & PLA (relative diff: 52% to FP
(p=0.0013), 56% to AZE (p=0.0004)) evident from treat-
ment day 1 vs FP (p=0.0072), AZE (p=0.0336) or PLA
(p<0.0001) and sustained for 14 days. The level of relief
achieved by MP29-02* patients on Day 2 (-5.52) was not
achieved before Day 5 by FP patients or Day 8 by AZE
patients. This pattern of rapid, sustained and superior
symptom relief by MP29-02* was observed for each
nasal and ocular symptom, which was not the case with
FP and AZE. MP29-02* provided significantly superior
nasal congestion relief than FP or AZE from Day 2; the
level of congestion relief provided by MP29-02* on Day 2
(-0.77) was not achieved before Day 6 and Day 9 for FP
and AZE, respectively. MP29-02* provided significantly
superior ocular itching relief vs FP from Day 2 and vs
AZE from Day 3; the ocular itch relief provided by
MP29-02* on Day 2 (-0.77) was not achieved before Day
10 for FP-patients. Similarly, the level of ocular itch relief
provided by MP29-02* on Day 3 (-1.06) was not achieved
by AZE-patients before Day 11.
Conclusion
The consistent and rapid effect in alleviating all nasal and
ocular symptoms is unique to MP29-02* and contributes
to its superiority over AZE and FP. The time advantage
over firstline therapy in achieving significant relief and
sustained effect should improve patient concordance.
MP29-02* is considered a new standard of care in AR.
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